Risperidone
- PDF / 130,923 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 103 Downloads / 171 Views
1
Risperidone Dyslipidaemia and weight gain in a child, treated with eicosapentaenoic acid/docosahexaenoic acid: case report An 11-year-old boy developed dyslipidaemia and weight gain while receiving risperidone, and was successfully treated with eicosapentaenoic acid/docosahexaenoic acid [routes and frequencies not stated; not all dosages stated]. The boy, who had been diagnosed with a pervasive disorder not otherwise specified (NOS) at 3 years of age, was diagnosed with a psychotic disorder NOS with obsessive-compulsive traits and mild mental retardation. He began receiving sertraline and valproic acid, followed by risperidone; the dosage of risperidone was slowly titrated up to 0.5mg. Three months after starting risperidone, his bodyweight and lipid levels increased. He was advised to increase his physical exercise and reduce his food intake while maintaining a low cholesterol diet. However, his bodyweight and lipid levels continued to increase. After 10 months of risperidone therapy, his bodyweight had increased by more than 10% from baseline, and his total cholesterol, triglyceride and LDL cholesterol levels were 267, 224 and 191 mg/dL, respectively. The boy began receiving omega-3 fatty acid supplementation with eicosapentaenoic acid/ docosahexaenoic acid. Three months later, his bodyweight was stable and his total cholesterol, triglyceride and LDL cholesterol levels had decreased to 209, 176 and 114 mg/dL, with an increase in HDL cholesterol from 47 to 59 mg/dL. After stopping eicosapentaenoic acid/docosahexaenoic acid, his lipid levels increased and he experienced a 2.5kg weight gain. Eicosapentaenoic acid/docosahexaenoic acid was restarted. After 4 months, his bodyweight was stable and his total cholesterol, triglyceride and LDL cholesterol levels had decreased. Author comment: "On the basis of this report, a possible role of omega 3 fatty acid supplement in the treatment of antipsychotic-induced dyslipidemia could be hypothesized." Pisano S, et al. Antipsychotic-induced dyslipidemia treated with omega 3 fatty acid supplement in an 11-year-old psychotic child: A 1-year follow-up. Journal of Child and Adolescent Psychopharmacology 23: 139-141, No. 2, Mar 2013. Available 803086785 from: URL: http://dx.doi.org/10.1089/cap.2012.0060 - Italy
0114-9954/10/1451-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Reactions 11 May 2013 No. 1451
Data Loading...
